Acquisition of Elidel completed Meda's acquisition of global rights for Elidel (pimecrolimus 1% cream) - announced on 7 April 2011 - has been completed. About Elidel Elidel is a patent protected, specialty focused product for the treatment of atopic dermatitis (AD). Depending on the country, Elidel is indicated as a second-line therapy for the short and long-term management of the signs and symptoms of mild to moderate AD in adults and children two years of age and older. AD is a chronically relapsing inflammatory skin disease and the skin barrier plays an essential role in protection against AD flares. Elidel is the first non-steroidal topical cream treatment specifically developed for the treatment of AD. To date, Elidel has been studied in more than 60,000 patients. Elidel is approved and sold in more than 90 countries worldwide. For further inquiries, please contact: Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878
Acquisition of Elidel completed
| Source: Meda AB